Cancer has been at the helm of human health crisis over a long time. To date, there has not been a cure developed or invented to alleviate this pandemic altogether. The positive aspect around this dilemma is the fact that all concerned parties, the government, researchers, scientists and every other interested agency have not given up hope yet. The government has committed more resources regarding finances towards the research and drug development in the fight against cancer while the scientists sacrifice their time and dedicate it towards finding new treatments and therapies that are more effective and with fewer side effects to patients. Mikhail Blagosklonny is one man who has dedicated his valuable time towards the research on the link between cancer and aging. He has a firm conviction that cancer is curable.
Mikhail Blagosklonny is an Oncology Professor at the Roswell Park Cancer Institute. He became the great scientist he is through the study of Aging and Cancer in the First Pavlov State Medical University of St. Petersburg. He attained an MD in Internal Medicine and later on earned a Ph.D. in Experimental Medicine and Cardiology. Mikhail has served as an Associate Professor of Medicine at New York Medical College and then proceeded to work in Ordway Research Institute as the Senior Scientist. His vast experience and skills over his successful career have made him an excellent professor who is admired by many. His research encompassed Biogerontology, anti-aging drugs, cancer and targeted cancer therapies. It ranges from cellular and molecular biological studies to clinical investigations.
Mikhail Blagosklonny is currently the Editor in Chief of Oncotarget and Cell Cycle. Also, he is the Associate Editor of Cancer Biology and Therapy. He serves on the Cell Death and Differentiation Editorial Board. Mikhail is a staunch supporter of Rapamycin, a cancer treatment drug that extends life. His keen interest in oncology has led him to believe that it is possible to control aging and cancer. His efforts towards the understanding, minimizing and ultimately curing age-related impairments have led him to develop a hypothesis on TOR gesturing its potential role in aging and cancer.
Moreover, Mikhail Blagosklonny is a recognized author. His work revolves about hyper-function theories on aging, cell cyclotherapy, and chemotherapeutic engineering. He has over 300 research articles, book chapters, and reviews. Besides, he serves as an Associate Editor for PLOS ONE, an American Journal of Pathology and International Journal of Cancer. View Mikhail’s profile on Google Scholar
Mikhail Blagosklonny is a hard worker, and his work commitments are high up the roof. As a result, he has attained numerous achievements in Oncology worldwide. He states that the great love he has for humanity and vision to live in a pandemic free society is what drives him in his line of duty.